Bos Sci's Ion, Taxus Libert nab FDA approval for acute MI patients

Justine Varieur Cadet | | Health Imaging | Screening
Boston Scientific's Ion paclitaxel-eluting platinum chromium coronary stent system and Taxus Liberté paclitaxel-eluting coronary stent system have received FDA approval for use in patients experiencing acute MI (AMI).

Currently, they are the only drug-eluting stent (DES) systems in the U.S. with an approved indication to treat patients with AMI. The new indication is a result of FDA review of data from the Paclitaxel (Taxus) clinical program and HORIZONS-AMI trial.

The company said the Ion stent system incorporates a platinum chromium alloy designed specifically for coronary stenting and the acute performance of coronary stent implantation in the treatment of coronary artery disease.

Justine Varieur Cadet

Related Content

Rising rates of interval breast cancers have experts calling for more risk-based screenings
Rates of breast cancer diagnosis, death expected to climb in coming decades
AI quantifies breast arterial calcifications on mammograms
AI 'not safe' to be implemented as a solo reader for breast cancer screening exams
American College of Radiology announces significant expansion of Lung Cancer Screening Registry
AI beats standard regression models at predicting lung cancer risk

Around the web

Cardiovascular Business
GE HealthCare launches new cardiac CT scanner with advanced AI capabilities

GE HealthCare designed the new-look Revolution Vibe CT scanner to help hospitals and health systems embrace CCTA and improve overall efficiency.

Cardiovascular Business
Bracco updates HeartSee coronary flow capacity software with new diagnostic features

Clinicians have been using HeartSee to diagnose and treat coronary artery disease since the technology first debuted back in 2018. These latest updates, set to roll out to existing users, are designed to improve diagnostic performance and user access.

Cardiovascular Business
Key trends in diagnostic heart testing: CT on the rise as some traditional techniques fall out of favor

The cardiac technologies clinicians use for CVD evaluations have changed significantly in recent years, according to a new analysis of CMS data. While some modalities are on the rise, others are being utilized much less than ever before.